Drugs / LY900009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01158404 | Jul 2010 → Aug 2012 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY900009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01158404 ↗ |
| Action | Inhibit | “small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein” PMID 26798966 ↗ Jan 2016 |
| Modality | Small molecule | “LY900009 is a small molecule inhibitor of Notch signalling” PMID 26798966 ↗ Jan 2016 |
| Route | Oral | “LY900009 was taken orally thrice weekly” PMID 26798966 ↗ Jan 2016 |